A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab-Reference-Cited by-同舟云学术

A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab

Published:2019-04-02 Issue: Volume: Page:
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Stader Felix¹²³,Penny Melissa A.²³,Siccardi Marco⁴,Marzolini Catia¹³

Affiliation:

1. Division of Infectious Diseases and Hospital EpidemiologyDepartments of Medicine and Clinical ResearchUniversity Hospital Basel Basel Switzerland

2. Infectious Disease Modelling UnitDepartment of Epidemiology and Public HealthSwiss Tropical and Public Health Institute Basel Switzerland

3. University of Basel Basel Switzerland

4. Department of Molecular and Clinical PharmacologyInstitute of Translational MedicineUniversity of Liverpool Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12399

Reference62 articles.

1. Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

2. U.S. Food and Drug Administration.Physiologically based pharmacokinetic analysis – format and content. Guidance for industry (2016). Accessed January 2 2018.

3. European Medicines Agency.Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation (2016). Accessed January 2 2018.

4. Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach

5. Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates;The Journal of Clinical Pharmacology;2024-09-03

2. Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study;Open Forum Infectious Diseases;2024-03-21

3. Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs;CPT: Pharmacometrics & Systems Pharmacology;2024-03

4. Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study;Clinical Infectious Diseases;2024-02-03

5. A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis;Frontiers in Pharmacology;2024-01-04